Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
Significant achievements in the systemic treatment of both advanced breast cancer and advanced colorectal cancer over the past 10 years have led to a growing number of drugs, combinations, and sequences to be tested. The choice of surrogate and true end points has become a critical issue and one that is currently the subject of much debate. Many recent randomized trials in solid tumor oncology have used progression-free survival (PFS) as the primary end point. PFS is an attractive end point because it is available earlier than overall survival (OS) and is not influenced by second-line treatments. PFS is now undergoing validation as a surrogate end point in various disease settings. The question of whether PFS can be considered an acceptable surrogate end point depends not only on formal validation studies but also on a standardized definition and unbiased ascertainment of disease progression in clinical trials. In advanced breast cancer, formal validation of PFS as a surrogate for OS has so far been unsuccessful. In advanced colorectal cancer, in contrast, current evidence indicates that PFS is a valid surrogate for OS after first-line treatment with chemotherapy. The other question is whether PFS sufficiently reflects clinical benefit to be considered a true end point in and of itself.
Saad
E D
ED
Dendrix Research, Hospital Sírio-Libanes, Sao Paulo, Brazil. everardo@dendrix.com.br
Katz
A
A
Hoff
P M
PM
Buyse
M
M
D015415:Biomarkers; D001943:Breast Neoplasms / Q000401:mortality*; D015179:Colorectal Neoplasms / Q000401:mortality*; D018572:Disease-Free Survival; D015340:Epidemiologic Research Design; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D015415:Biomarkers